DK0874830T3 - Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf - Google Patents

Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf

Info

Publication number: DK0874830T3
Authority: DK; Denmark
Prior art keywords: pharmaceutical; preparation; metalloproteinase inhibitor; preparation containing; pharmaceutical use
Prior art date: 1995-12-08

Application number

DK96944229T

Other languages

Danish (da)

English (en)

Inventor

Scott E Zook

Raymond Dagnino Jr

Michael E Deason

Steven L Bender

Michael J Melnick

Original Assignee

Agouron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-08

Filing date

1996-12-05

Publication date

2003-04-22

1996-12-05 Application filed by Agouron Pharma filed Critical Agouron Pharma

2003-04-22 Application granted granted Critical

2003-04-22 Publication of DK0874830T3 publication Critical patent/DK0874830T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Oncology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

DK96944229T 1995-12-08 1996-12-05 Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf DK0874830T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US56976695A	1995-12-08	1995-12-08
PCT/US1996/019328 WO1997020824A1 (en)	1995-12-08	1996-12-05	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation

Publications (1)

Publication Number	Publication Date
DK0874830T3 true DK0874830T3 (da)	2003-04-22

Family

ID=24276764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96944229T DK0874830T3 (da)	1995-12-08	1996-12-05	Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf

Country Status (39)

Country	Link
US (1)	US6153757A (es)
EP (2)	EP1095936B1 (es)
JP (1)	JP2000502330A (es)
KR (1)	KR19990072009A (es)
CN (2)	CN1542002A (es)
AP (2)	AP1368A (es)
AT (2)	ATE234291T1 (es)
AU (1)	AU725831C (es)
BG (1)	BG64279B1 (es)
BR (1)	BR9611929A (es)
CA (1)	CA2238306A1 (es)
CO (1)	CO4790150A1 (es)
CZ (1)	CZ292942B6 (es)
DE (2)	DE69626684T2 (es)
DK (1)	DK0874830T3 (es)
EA (1)	EA003294B1 (es)
ES (2)	ES2195034T3 (es)
GE (1)	GEP20012388B (es)
GT (2)	GT199700015AA (es)
HR (1)	HRP970031A2 (es)
HU (1)	HUP9902092A3 (es)
ID (1)	ID17624A (es)
IL (6)	IL138027A (es)
MX (1)	MX9804457A (es)
MY (1)	MY117290A (es)
NO (1)	NO311360B1 (es)
NZ (1)	NZ325559A (es)
OA (1)	OA10794A (es)
PA (1)	PA8431301A1 (es)
PE (1)	PE69298A1 (es)
PL (1)	PL327275A1 (es)
PT (1)	PT874830E (es)
SI (1)	SI0874830T1 (es)
SK (1)	SK73898A3 (es)
SV (1)	SV1997000008A (es)
TR (1)	TR199800990T2 (es)
TW (1)	TW546293B (es)
WO (1)	WO1997020824A1 (es)
YU (1)	YU21597A (es)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6500948B1 (en)	1995-12-08	2002-12-31	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
EP1095936B1 (en) *	1995-12-08	2004-11-24	Agouron Pharmaceuticals, Inc.	Intermediates useful for the preparation of metallproteinase inhibitors
DE69719538T2 (de) *	1996-07-22	2004-02-19	Monsanto Co.	Thiol-sulfonen als metalloproteinaseinhibitoren
US6747027B1 (en)	1996-07-22	2004-06-08	Pharmacia Corporation	Thiol sulfonamide metalloprotease inhibitors
EP0927161B1 (en)	1996-08-28	2002-10-16	The Procter & Gamble Company	Substituted cyclic amine metalloprotease inhibitors
PL331838A1 (en) *	1996-08-28	1999-08-02	Procter & Gamble	1,3-diheterocyclic inhibitors of metaloproteases
US6872742B2 (en)	1996-08-28	2005-03-29	The Procter & Gamble Company	Substituted cyclic amine metalloprotease inhibitors
WO1998008827A1 (en) *	1996-08-28	1998-03-05	The Procter & Gamble Company	Heterocyclic metalloprotease inhibitors
BR9712792A (pt) *	1996-08-28	1999-12-14	Procter & Gamble	Inibidores de metaloprotease bidentada.
IL128664A (en) *	1996-08-28	2003-07-06	Procter & Gamble	Heterocyclic metalloprotease inhibitors and pharmaceutical compositions comprising them
US5977408A (en) *	1996-10-16	1999-11-02	American Cyanamid Company	Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5962481A (en) *	1996-10-16	1999-10-05	American Cyanamid Company	Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6228869B1 (en)	1996-10-16	2001-05-08	American Cyanamid Company	Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5929097A (en) *	1996-10-16	1999-07-27	American Cyanamid Company	Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
IL129148A0 (en) *	1996-10-16	2000-02-17	American Cyanamid Co	The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6548524B2 (en)	1996-10-16	2003-04-15	American Cyanamid Company	Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6174915B1 (en)	1997-03-25	2001-01-16	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) *	1996-10-24	1999-12-28	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
CA2275478A1 (en)	1996-12-17	1998-06-25	Kentaro Sato	Piperazine compounds as inhibitors of mmp or tnf
DE69819878T2 (de)	1997-03-04	2004-04-22	Monsanto Co.	Divalente sulfonyl-aryl-oder heteroaryl hydroxamsäureverbindungen
US7115632B1 (en)	1999-05-12	2006-10-03	G. D. Searle & Co.	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6087359A (en) *	1997-03-04	2000-07-11	Getman; Daniel P.	Thioaryl sulfonamide hydroxamic acid compounds
US6696449B2 (en)	1997-03-04	2004-02-24	Pharmacia Corporation	Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US6794511B2 (en)	1997-03-04	2004-09-21	G. D. Searle	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
DK0977745T3 (da) *	1997-03-04	2005-03-14	Pharmacia Corp	Thioarylsulfonamidhydroxamsyreforbindelser
WO1998039316A1 (en)	1997-03-04	1998-09-11	Monsanto Company	N-hydroxy 4-sulfonyl butanamide compounds
WO1998039326A1 (en)	1997-03-04	1998-09-11	Monsanto Company	Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6638952B1 (en)	1997-03-04	2003-10-28	Pharmacia Corporation	Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US5985900A (en) *	1997-04-01	1999-11-16	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP2001521504A (ja) *	1997-04-01	2001-11-06	アグロン・ファーマシュウティカルズ・インコーポレーテッド	メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用
WO1998050348A1 (en) *	1997-05-09	1998-11-12	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP2004137284A (ja) *	1997-06-17	2004-05-13	Kaken Pharmaceut Co Ltd	２−スルファモイル安息香酸誘導体
NZ503945A (en)	1997-07-31	2002-11-26	Procter & Gamble	Metalloprotease-inhibiting amide derivatives
US6403632B1 (en) *	2000-03-01	2002-06-11	Bristol Myers Squibb Pharma Co	Lactam metalloprotease inhibitors
JPH11199512A (ja) *	1997-10-24	1999-07-27	Pfizer Prod Inc	変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
US20010039287A1 (en)	1997-11-14	2001-11-08	Thomas E Barta	Aromatic sulfone hydroxamic acid metalloprotease inhibitor
AU756150C (en)	1997-11-14	2004-03-04	G.D. Searle & Co.	Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en)	1997-11-14	2004-06-15	Pharmacia Corporation	Aromatic sulfone hydroxamic acid metalloprotease inhibitor
IL137162A0 (en) *	1998-01-27	2001-07-24	American Cyanamid Co	2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors
US6071903A (en) *	1998-01-27	2000-06-06	American Cyanamid Company	2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
US6410580B1 (en)	1998-02-04	2002-06-25	Novartis Ag	Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
HUP0101176A3 (en)	1998-02-04	2002-06-28	Novartis Ag	Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them
US6329418B1 (en)	1998-04-14	2001-12-11	The Procter & Gamble Company	Substituted pyrrolidine hydroxamate metalloprotease inhibitors
AU3982599A (en)	1998-05-14	1999-11-29	Du Pont Pharmaceuticals Company	Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
JP2002518368A (ja)	1998-06-17	2002-06-25	デュポンファーマシューティカルズカンパニー	メタロプロテイナーゼ阻害剤としての環式ヒドロキサム酸類
EP1357109B1 (en)	1998-06-18	2008-07-23	F. Hoffmann-La Roche Ag	Process for aryl alkyl sulfide
FR2780402B1 (fr) *	1998-06-30	2001-04-27	Adir	Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA59453C2 (uk) *	1998-08-12	2003-09-15	Пфайзер Продактс Інк.	Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
DE69925840T2 (de) *	1998-08-12	2006-05-04	Pfizer Products Inc., Groton	Tace inhibitoren
US6509337B1 (en) *	1998-09-17	2003-01-21	Pfizer Inc.	Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6300341B1 (en)	1998-09-30	2001-10-09	The Procter & Gamble Co.	2-substituted heterocyclic sulfonamides
US6307049B1 (en)	1998-09-30	2001-10-23	The Procter & Gamble Co.	Heterocyclic 2-substituted ketoamides
BR9914196A (pt) *	1998-09-30	2001-06-19	Procter & Gamble	Processo de tratamento da perda de cabelo
US6288261B1 (en) *	1998-12-18	2001-09-11	Abbott Laboratories	Inhibitors of matrix metalloproteinases
US6858598B1 (en) *	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1140194A2 (en) *	1998-12-23	2001-10-10	G.D. SEARLE & CO.	Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
US6326516B1 (en)	1999-01-27	2001-12-04	American Cyanamid Company	Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
CN1178915C (zh)	1999-01-27	2004-12-08	惠氏控股有限公司	含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途
AR022423A1 (es) *	1999-01-27	2002-09-04	American Cyanamid Co	Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
US6762178B2 (en)	1999-01-27	2004-07-13	Wyeth Holdings Corporation	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en)	1999-01-27	2002-01-22	American Cyanamid Company	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6225311B1 (en)	1999-01-27	2001-05-01	American Cyanamid Company	Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6313123B1 (en)	1999-01-27	2001-11-06	American Cyanamid Company	Acetylenic sulfonamide thiol tace inhibitors
US6544984B1 (en)	1999-01-27	2003-04-08	American Cyanamid Company	2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
US6200996B1 (en)	1999-01-27	2001-03-13	American Cyanamid Company	Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6753337B2 (en)	1999-01-27	2004-06-22	Wyeth Holdings Corporation	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6277885B1 (en)	1999-01-27	2001-08-21	American Cyanamid Company	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en)	1999-01-27	2005-09-20	Wyeth Holdings Corporation	Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6800646B1 (en)	1999-02-08	2004-10-05	Pharmacia Corporation	Sulfamato hydroxamic acid metalloprotease inhibitor
EA005500B1 (ru)	1999-02-08	2005-02-24	Дж.Д. Сирл Ллк	Сульфаматогидроксамовая кислота как ингибитор металлопротеаз
EP1165530A2 (en)	1999-03-03	2002-01-02	The Procter & Gamble Company	Dihetero-substituted metalloprotease inhibitors
EP1165501A1 (en)	1999-03-03	2002-01-02	The Procter & Gamble Company	Alkenyl- and alkynyl-containing metalloprotease inhibitors
AUPP982399A0 (en) *	1999-04-19	1999-05-13	Fujisawa Pharmaceutical Co., Ltd.	Mmp inhibitor
US6583299B1 (en)	1999-05-20	2003-06-24	G.D. Searle & Co.	α-amino-β-sulfonyl hydroxamic acid compounds
US6869951B1 (en)	1999-07-16	2005-03-22	Pharmacia Corporation	Method of changing conformation of a matrix metalloproteinase
AR033651A1 (es)	1999-10-01	2004-01-07	Hoffmann La Roche	Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento
ATE260272T1 (de)	2000-03-17	2004-03-15	Bristol Myers Squibb Pharma Co	Beta-aminsäure-derivate zur verwendung als matrix-metalloproteasen- und tna-alpha-inhibitoren
AU2001250849A1 (en)	2000-03-17	2001-10-03	Bristol-Myers Squibb Pharma Company	Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
EP1138680A1 (en) *	2000-03-29	2001-10-04	Pfizer Products Inc.	Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
CA2372352A1 (en) *	2000-04-07	2001-10-18	Hyun-Gyu Park	Sulfonamide derivative as a matrix metalloproteinase inhibitor
US6683093B2 (en)	2000-05-12	2004-01-27	Pharmacia Corporation	Aromatic sulfone hydroxamic acids and their use as protease inhibitors
US6927216B2 (en)	2000-10-03	2005-08-09	Bristol-Myers Squibb Pharma Company	Cyclic sulfonyl compounds as inhibitors of metalloproteases
FR2819252A1 (fr) *	2001-01-11	2002-07-12	Servier Lab	Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6642255B2 (en)	2001-01-11	2003-11-04	Bristol-Myers Squibb Pharma Company	1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
WO2002055516A2 (en)	2001-01-11	2002-07-18	Bristol Myers Squibb Co	1,1-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLOPROTEASE AND TNF-$g(a)
MXPA01013326A (es)	2001-02-14	2002-08-26	Warner Lambert Co	Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
US6720329B2 (en)	2001-03-15	2004-04-13	Bristol-Myers Squibb Pharma	Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE)
US6716845B2 (en)	2001-03-30	2004-04-06	Hoffmann-La Roche Inc.	Barbituric acid derivatives
JP2004530691A (ja)	2001-05-11	2004-10-07	ファルマシア・コーポレーション	芳香族スルホンヒドロキサメートおよびプロテアーゼ阻害剤としてのそれらの使用
EP1404325A2 (en) *	2001-05-29	2004-04-07	Guilford Pharmaceuticals Inc.	Method for treating nerve injury caused by surgery
US6683078B2 (en)	2001-07-19	2004-01-27	Pharmacia Corporation	Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
AUPR726201A0 (en) *	2001-08-24	2001-09-20	Fujisawa Pharmaceutical Co., Ltd.	New use of a cyclic compound
JP2003081937A (ja) *	2001-09-07	2003-03-19	Bayer Ag	ベンゼンスルホンアミド誘導体
BR0213736A (pt)	2001-11-01	2004-10-19	Wyeth Corp	ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
AU2002356979A1 (en) *	2001-11-30	2003-06-17	Bristol-Myers Squibb Company	Method of producing n-((2s)-sulfanyl-4-(1,5,5-trimethylhydantoinyl)butanoyl)-l-leucyl-l-tert-leucine n-methylamide and intermediate thereof
PE20030701A1 (es)	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
WO2003091247A2 (en)	2002-04-25	2003-11-06	Pharmacia Corporation	Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
AU2003233154A1 (en)	2002-06-10	2003-12-22	Pfizer Inc.	Metabolites of prinomastat and their sythesis
EP1511488B1 (en) *	2002-06-12	2013-05-22	Symphony Evolution, Inc.	Human adam-10 inhibitors
JP2006502980A (ja) *	2002-06-25	2006-01-26	ファルマシア・コーポレーション	アリールスルホニルヒドロキサム酸およびアミド誘導体、ならびにプロテアーゼ阻害薬としてのそれらの使用
AU2003304456A1 (en)	2002-12-23	2005-03-16	Wyeth Holdings Corporation	Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
ES2324535T3 (es) *	2003-02-14	2009-08-10	Merck Serono Sa	Derivados de la piperazina-2-carboxamida.
WO2004073599A2 (en) *	2003-02-18	2004-09-02	Pfizer Inc.	Inhibitors of hepatitis c virus, compositions and treatments using the same
BRPI0408682A (pt)	2003-03-24	2006-03-28	Actimis Pharmaceuticals Inc	derivado de benzenossulfonamida, medicamento, uso do derivado de benzenossulfonamida, e, processo para controlar uma doença ou distúrbio inflamatórios ou imuno-reguladores em humanos e animais
GT200500139A (es) *	2004-06-08	2005-07-25		Metodo para la preparacion de acidos hidroxamicos
US20100226922A1 (en) *	2006-06-08	2010-09-09	Dorothea Maetzel	Specific protease inhibitors and their use in cancer therapy
WO2009052200A2 (en) *	2007-10-16	2009-04-23	Symphony Evolution, Inc.	Human adam-10 inhibitors
EP2147684A1 (en) *	2008-07-22	2010-01-27	Bracco Imaging S.p.A	Diagnostic Agents Selective Against Metalloproteases
WO2011081884A1 (en)	2009-12-14	2011-07-07	Massachusetts Institute Of Technology	Systems and methods related to optical nanosensors including photoluminescent nanostructures
IT1401253B1 (it)	2010-04-23	2013-07-18	Uni Degli Studi Carlo Bo Urbino	Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
EP2763972A1 (en) *	2011-10-04	2014-08-13	Institut National de la Sante et de la Recherche Medicale (INSERM)	New apoptosis inducing compounds
CA3115038A1 (en)	2018-10-04	2020-04-09	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Egfr inhibitors for treating keratodermas
WO2020218316A1 (ja) *	2019-04-26	2020-10-29	日産化学株式会社	アリールスルホン酸エステル化合物の製造方法
WO2020252439A1 (en) *	2019-06-14	2020-12-17	Loyola University Of Chicago	Carborane hydroxamic acid matrix metalloproteinase agents for boron neutron capture therapy

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4032639A (en) *	1976-03-22	1977-06-28	American Home Products Corporation	2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
ZW23187A1 (en) *	1986-12-15	1988-06-29	Hoffmann La Roche	Phosphinic acid derivatives
GB9000846D0 (en) *	1990-01-15	1990-03-14	Beecham Group Plc	Novel compounds
GB9022117D0 (en) *	1990-10-11	1990-11-21	Beecham Group Plc	Novel compounds
US5239078A (en) *	1990-11-21	1993-08-24	Glycomed Incorporated	Matrix metalloprotease inhibitors
US5183900A (en) *	1990-11-21	1993-02-02	Galardy Richard E	Matrix metalloprotease inhibitors
US5189178A (en) *	1990-11-21	1993-02-23	Galardy Richard E	Matrix metalloprotease inhibitors
KR927003520A (ko) *	1990-12-03	1992-12-18	죤 에드워드 베리만	펩티딜(peptidyl) 유도체
JPH06508135A (ja) *	1991-05-28	1994-09-14	メルク　エンド　カンパニー　インコーポレーテッド	抗変性活性剤としての置換ｎ−カルボキシアルキルペプチジル誘導体
US5256657A (en) *	1991-08-19	1993-10-26	Sterling Winthrop, Inc.	Succinamide derivative matrix-metalloprotease inhibitors
GB9211707D0 (en) *	1992-06-03	1992-07-15	Celltech Ltd	Peptidyl derivatives
GB9211706D0 (en) *	1992-06-03	1992-07-15	Celltech Ltd	Peptidyl derivatives
US5376664A (en) *	1992-07-27	1994-12-27	The Du Pont Merck Pharmaceutical Company	Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
EP0671911A4 (en) *	1992-11-25	1996-08-21	Merck & Co Inc	CARBOXY-PEPTIDYL DERIVATIVES FOR USE AS ACTIVE ANTI-DEGENERATIVE AGENTS.
US5455258A (en) *	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) *	1993-01-06	1996-04-09	Ciba-Geigy Corporation	Arylsufonamido-substituted hydroxamic acids
US5552419A (en) *	1993-01-06	1996-09-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
GB9307956D0 (en) *	1993-04-17	1993-06-02	Walls Alan J	Hydroxamic acid derivatives
GB9308695D0 (en) *	1993-04-27	1993-06-09	Celltech Ltd	Peptidyl derivatives
JPH09501430A (ja) *	1993-08-05	1997-02-10	シンテックス（ユー・エス・エイ）・インコーポレイテッド	マトリックスメタロプロテアーゼ阻害因子
US6013792A (en) *	1993-08-05	2000-01-11	Syntex (U.S.A.), Inc.	Matrix metalloprotease inhibitors
UA48121C2 (uk) *	1993-11-04	2002-08-15	Сінтекс (С.Ш.А.) Інк.	Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
US6037472A (en) *	1993-11-04	2000-03-14	Syntex (U.S.A.) Inc.	Matrix metalloprotease inhibitors
DE69529100T2 (de) *	1994-01-22	2003-07-17	British Biotech Pharm	Metalloproteinaseinhibitoren
US5514716A (en) *	1994-02-25	1996-05-07	Sterling Winthrop, Inc.	Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
EP0763012B1 (en) *	1994-05-28	1999-06-09	British Biotech Pharmaceuticals Limited	Succinyl hydroxamic acid, n-formyl-n-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
US5962529A (en) *	1994-06-22	1999-10-05	British Biotech Pharmaceuticals Limited	Metalloproteinase inhibitors
GB9416897D0 (en) *	1994-08-20	1994-10-12	British Biotech Pharm	Metalloproteinase inhibitors
GB9423914D0 (en) *	1994-11-26	1995-01-11	British Biotech Pharm	Polyether derivatives as metalloproteinase inhibitors
US5863949A (en) *	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
US5861510A (en) *	1995-04-20	1999-01-19	Pfizer Inc	Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
KR980009238A (ko) *	1995-07-28	1998-04-30	우에노 도시오	설포닐아미노산 유도체
DE69624536T2 (de) *	1995-08-08	2003-06-05	Ono Pharmaceutical Co	Hydroxamsäurederivate verwendbar zur Hemmung von Gelatinase
TR199800849T2 (xx) *	1995-11-13	1998-07-21	Hoechst Aktiengesellschaft	Siklikle heterosiklik N-ikame edilmi� alfa-iminohidroksamla karbon asitleri
DE19542189A1 (de) *	1995-11-13	1997-05-15	Hoechst Ag	Cyclische N-substituierte alpha-Iminohydroxamsäuren
ES2184893T3 (es) *	1995-11-17	2003-04-16	Warner Lambert Co	Inhibidores de sulfonamida de lasd metaloproteinasas matricales.
EP1095936B1 (en) *	1995-12-08	2004-11-24	Agouron Pharmaceuticals, Inc.	Intermediates useful for the preparation of metallproteinase inhibitors
US5753653A (en) *	1995-12-08	1998-05-19	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
TW453995B (en) *	1995-12-15	2001-09-11	Novartis Ag	Certain alpha-substituted arylsulfonamido acetohydroxamic acids
DK0780386T3 (da) *	1995-12-20	2003-02-03	Hoffmann La Roche	Matrixmetalloproteaseinhibitorer
US6008220A (en) *	1995-12-22	1999-12-28	Warner Lambert Company	Aromatic keto-acids and their derivatives as inhibitors of matrix metalloproteinases
US5837224A (en) *	1996-01-19	1998-11-17	The Regents Of The University Of Michigan	Method of inhibiting photoaging of skin
BR9707010B1 (pt) *	1996-01-23	2009-05-05		compostos, composição farmacêutica e composições para inibir metaloproteinase e colagenase do tipo iv.
WO1998007697A1 (en) *	1996-08-23	1998-02-26	Pfizer Inc.	Arylsulfonylamino hydroxamic acid derivatives
WO1998008827A1 (en) *	1996-08-28	1998-03-05	The Procter & Gamble Company	Heterocyclic metalloprotease inhibitors
EP0927161B1 (en) *	1996-08-28	2002-10-16	The Procter & Gamble Company	Substituted cyclic amine metalloprotease inhibitors
US5929097A (en) *	1996-10-16	1999-07-27	American Cyanamid Company	Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5985900A (en) *	1997-04-01	1999-11-16	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

1996
- 1996-12-05 EP EP00128719A patent/EP1095936B1/en not_active Expired - Lifetime
- 1996-12-05 GE GEAP19964389A patent/GEP20012388B/en unknown
- 1996-12-05 AT AT96944229T patent/ATE234291T1/de not_active IP Right Cessation
- 1996-12-05 IL IL13802796A patent/IL138027A/en not_active IP Right Cessation
- 1996-12-05 PT PT96944229T patent/PT874830E/pt unknown
- 1996-12-05 TR TR1998/00990T patent/TR199800990T2/xx unknown
- 1996-12-05 CN CNA2004100335232A patent/CN1542002A/zh active Pending
- 1996-12-05 PL PL96327275A patent/PL327275A1/xx unknown
- 1996-12-05 US US09/011,971 patent/US6153757A/en not_active Expired - Fee Related
- 1996-12-05 WO PCT/US1996/019328 patent/WO1997020824A1/en not_active Application Discontinuation
- 1996-12-05 DE DE69626684T patent/DE69626684T2/de not_active Expired - Fee Related
- 1996-12-05 AP APAP/P/1998/001284A patent/AP1368A/en active
- 1996-12-05 CZ CZ19981733A patent/CZ292942B6/cs not_active IP Right Cessation
- 1996-12-05 DE DE69633947T patent/DE69633947T2/de not_active Expired - Fee Related
- 1996-12-05 AT AT00128719T patent/ATE283264T1/de not_active IP Right Cessation
- 1996-12-05 BR BR9611929A patent/BR9611929A/pt active Search and Examination
- 1996-12-05 HU HU9902092A patent/HUP9902092A3/hu unknown
- 1996-12-05 AU AU14091/97A patent/AU725831C/en not_active Ceased
- 1996-12-05 ES ES96944229T patent/ES2195034T3/es not_active Expired - Lifetime
- 1996-12-05 SK SK738-98A patent/SK73898A3/sk unknown
- 1996-12-05 CN CNB961995831A patent/CN1207289C/zh not_active Expired - Fee Related
- 1996-12-05 KR KR1019980704301A patent/KR19990072009A/ko not_active Application Discontinuation
- 1996-12-05 EA EA199800541A patent/EA003294B1/ru not_active IP Right Cessation
- 1996-12-05 IL IL12455996A patent/IL124559A/en not_active IP Right Cessation
- 1996-12-05 SI SI9630588T patent/SI0874830T1/xx unknown
- 1996-12-05 AP APAP/P/2001/002270A patent/AP1288A/en active
- 1996-12-05 IL IL13481696A patent/IL134816A/xx not_active IP Right Cessation
- 1996-12-05 CA CA002238306A patent/CA2238306A1/en not_active Abandoned
- 1996-12-05 JP JP9521405A patent/JP2000502330A/ja not_active Ceased
- 1996-12-05 DK DK96944229T patent/DK0874830T3/da active
- 1996-12-05 ES ES00128719T patent/ES2233275T3/es not_active Expired - Lifetime
- 1996-12-05 NZ NZ325559A patent/NZ325559A/xx unknown
- 1996-12-05 EP EP96944229A patent/EP0874830B1/en not_active Expired - Lifetime
1997
- 1997-01-18 MY MYPI97000193A patent/MY117290A/en unknown
- 1997-01-22 HR HR96/019,328A patent/HRP970031A2/hr not_active Application Discontinuation
- 1997-01-23 TW TW086100726A patent/TW546293B/zh not_active IP Right Cessation
- 1997-01-29 GT GT199700015AK patent/GT199700015AA/es unknown
- 1997-01-29 GT GT199700015A patent/GT199700015A/es unknown
- 1997-02-06 SV SV1997000008A patent/SV1997000008A/es not_active Application Discontinuation
- 1997-02-12 CO CO97007169A patent/CO4790150A1/es unknown
- 1997-05-26 YU YU21597A patent/YU21597A/sr unknown
- 1997-05-27 PE PE1997000427A patent/PE69298A1/es not_active Application Discontinuation
- 1997-05-30 PA PA19978431301A patent/PA8431301A1/es unknown
- 1997-06-02 ID IDP971874A patent/ID17624A/id unknown
1998
- 1998-06-03 OA OA9800074A patent/OA10794A/en unknown
- 1998-06-04 MX MX9804457A patent/MX9804457A/es not_active IP Right Cessation
- 1998-06-05 NO NO19982590A patent/NO311360B1/no unknown
- 1998-06-05 BG BG102510A patent/BG64279B1/bg unknown
2000
- 2000-08-23 IL IL13802800A patent/IL138028A0/xx unknown
- 2000-08-23 IL IL13802700A patent/IL138027A0/xx unknown
2001
- 2001-06-11 IL IL14367401A patent/IL143674A0/xx unknown

Also Published As

Publication number	Publication date
GEP20012388B (en)	2001-03-25
PL327275A1 (en)	1998-12-07
BR9611929A (pt)	1999-05-18
HUP9902092A3 (en)	2000-12-28
IL134816A (en)	2003-02-12
PE69298A1 (es)	1998-11-13
NZ325559A (en)	2000-01-28
SI0874830T1 (en)	2003-08-31
IL124559A (en)	2004-07-25
AU725831B2 (en)	2000-10-19
AP9801284A0 (en)	1998-09-30
PT874830E (pt)	2003-06-30
CZ173398A3 (cs)	1998-11-11
CN1207289C (zh)	2005-06-22
IL143674A0 (en)	2002-04-21
CA2238306A1 (en)	1997-06-12
ATE283264T1 (de)	2004-12-15
DE69626684D1 (de)	2003-04-17
DE69633947T2 (de)	2005-12-01
HRP970031A2 (en)	1998-08-31
MY117290A (en)	2004-06-30
EP0874830B1 (en)	2003-03-12
NO982590D0 (no)	1998-06-05
ID17624A (id)	1998-01-15
IL138027A0 (en)	2001-10-31
BG102510A (en)	1999-08-31
SV1997000008A (es)	1999-02-15
IL138028A0 (en)	2001-10-31
AP1368A (en)	2005-04-21
NO982590L (no)	1998-08-05
YU21597A (en)	1999-11-22
EA003294B1 (ru)	2003-04-24
AU1409197A (en)	1997-06-27
MX9804457A (es)	1998-09-30
SK73898A3 (en)	1999-01-11
EP1095936A1 (en)	2001-05-02
BG64279B1 (bg)	2004-08-31
CO4790150A1 (es)	1999-05-31
CN1542002A (zh)	2004-11-03
ES2195034T3 (es)	2003-12-01
AP1288A (en)	2004-07-21
IL138027A (en)	2004-08-31
KR19990072009A (ko)	1999-09-27
IL124559A0 (en)	1998-12-06
CZ292942B6 (cs)	2004-01-14
EP1095936B1 (en)	2004-11-24
ES2233275T3 (es)	2005-06-16
IL134816A0 (en)	2001-05-20
EA199800541A1 (ru)	1998-12-24
DE69633947D1 (de)	2004-12-30
CN1207734A (zh)	1999-02-10
GT199700015A (es)	1998-07-23
NO311360B1 (no)	2001-11-19
GT199700015AA (es)	1998-07-23
HUP9902092A2 (hu)	1999-09-28
AP2001002270A0 (en)	2001-09-30
TW546293B (en)	2003-08-11
EP0874830A1 (en)	1998-11-04
WO1997020824A1 (en)	1997-06-12
PA8431301A1 (es)	2000-05-24
JP2000502330A (ja)	2000-02-29
OA10794A (en)	2001-07-05
ATE234291T1 (de)	2003-03-15
AU725831C (en)	2002-10-17
TR199800990T2 (xx)	1998-07-21
US6153757A (en)	2000-11-28
DE69626684T2 (de)	2004-04-29

Publication	Publication Date	Title
DK0874830T3 (da)	2003-04-22	Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf
DK0811006T3 (da)	2003-08-04	Benzopyranholdige forbindelser og fremgangsmåde til deres anvendelse
DK0729956T3 (da)	2001-11-26	Benzothi9phenforbindelser, emllemprodukter, præparater og fremgangsmåder
NO20006716D0 (no)	2000-12-29	Proteaseinhibitorer
NO975411D0 (no)	1997-11-25	Tetnings- og forankringsinnretning for et brönnverktöy
DE69623709T2 (de)	2003-01-30	Vorrichtung zum Verabreichen von Medikamenten
DE69621026D1 (de)	2002-06-06	Zyklische gmp-spezifische phosphodiesteraseinhibitoren
NO964063L (no)	1997-04-01	System og fremgangsmåte for komplettering av en brönn
IS4771A (is)	1998-06-12	Interlevkín-1ß umbreytiensím tálmar
NO965294D0 (no)	1996-12-11	Emulsjon, kosmetisk og farmasöytisk preparat inneholdende denne samt anvendelse derav
EE9900517A (et)	2000-06-15	Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südameveresoonkonna haiguste ärahoidmiseks
FI973282A (fi)	1997-08-08	Trombiinin inhibiittoreita
NO974403L (no)	1997-11-17	Reversible proteasehemmere
DK0858464T3 (da)	2003-08-25	Thrombin-inhibitorer
DE69629142D1 (de)	2003-08-28	Verpackungs-Verfahren
DK378988D0 (da)	1988-07-07	Dopamin-beta-hydroxylaseinhibitorer, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende disse forbindelser
DK1003383T4 (da)	2010-01-25	Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
DK0909271T3 (da)	2002-01-28	Indolyl-pyrrolylidenmethylpyrrolderivater og en fremgangsmåde til fremstilling deraf
BR9610075A (pt)	1999-03-02	Inibidores prolil endopeptidase
DK0901320T3 (da)	2001-09-24	Dyreidentifikationsindretning til oral indgivelse
BR9610514A (pt)	1999-03-30	Inibidores cicloantihelmínticos
NO970481D0 (no)	1997-02-04	Emballasje samt fremgangsmåte og verktöy for fremstilling av denne
ITMI950384A0 (it)	1995-02-28	Apparecchio per aerosolterapia
KR970703937A (ko)	1997-08-09	금속단백질 분해효소 억제제(Metallproteinase inhibitors)
SE9303549D0 (sv)	1993-10-29	Förpackningssätt samt anordning härför